Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma DOI Open Access
Alisha Kashyap, Julia Dai, Xiao Ni

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 568 - 568

Published: Feb. 7, 2025

Background/Objectives: Cutaneous T-cell lymphoma (CTCL) is a rare group of non-Hodgkin lymphomas characterized by the clonal expansion malignant T cells. While current treatments can alleviate symptoms and significant progress has been made in treating leukemic CTCL, definitive cure remains elusive. Dysregulation Janus kinase/signal transducer activator transcription (JAK/STAT) signaling pathway key driver CTCL pathogenesis. As result, therapeutic strategies targeting JAK/STAT have gained momentum, with increasing use JAK inhibitors other agents that effectively suppress this pathway. These immune-modulating therapies broad effects on physiological processes, inflammation, pathological changes associated both inflammatory diseases cancers. Several inhibitors, originally FDA-approved for conditions, are now being investigated cancer treatment. Methods: In paper, brief review literature dysregulation provided, highlighting clinical preclinical studies involving target Results: Specifically, we focus six currently under investigation-golidocitinib, ruxolitinib, cerdulatinib, tofacitinib, upadacitinib, abrocitinib. Additionally, discuss explore mechanisms underlying inhibition CTCL. Furthermore, reported cases which relapsed or emerged following inhibitor Conclusions: Collectively, these findings support potential utility However, further research needed to evaluate safety risks, minimize adverse effects, optimize strategies.

Language: Английский

Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma DOI Open Access
Alisha Kashyap, Julia Dai, Xiao Ni

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 568 - 568

Published: Feb. 7, 2025

Background/Objectives: Cutaneous T-cell lymphoma (CTCL) is a rare group of non-Hodgkin lymphomas characterized by the clonal expansion malignant T cells. While current treatments can alleviate symptoms and significant progress has been made in treating leukemic CTCL, definitive cure remains elusive. Dysregulation Janus kinase/signal transducer activator transcription (JAK/STAT) signaling pathway key driver CTCL pathogenesis. As result, therapeutic strategies targeting JAK/STAT have gained momentum, with increasing use JAK inhibitors other agents that effectively suppress this pathway. These immune-modulating therapies broad effects on physiological processes, inflammation, pathological changes associated both inflammatory diseases cancers. Several inhibitors, originally FDA-approved for conditions, are now being investigated cancer treatment. Methods: In paper, brief review literature dysregulation provided, highlighting clinical preclinical studies involving target Results: Specifically, we focus six currently under investigation-golidocitinib, ruxolitinib, cerdulatinib, tofacitinib, upadacitinib, abrocitinib. Additionally, discuss explore mechanisms underlying inhibition CTCL. Furthermore, reported cases which relapsed or emerged following inhibitor Conclusions: Collectively, these findings support potential utility However, further research needed to evaluate safety risks, minimize adverse effects, optimize strategies.

Language: Английский

Citations

0